Single-use disposable dry powder inhalers for pulmonary drug delivery

Expert Opinion on Drug Delivery

Volumn 7, Issue 12, 2010, Pages 1359-1372

  Friebel, Christian ^a   Steckel, Hartwig ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

device; disposable; dry powder inhalation; single use

Indexed keywords

APOMORPHINE; CANNABINOID; DIHYDROERGOTAMINE; LOXAPINE; NICOTINE; OPIATE; OSELTAMIVIR; PHOSPHODIESTERASE V INHIBITOR; SEROTONIN 3 ANTAGONIST; TRIPTAN DERIVATIVE; ZANAMIVIR;

AGITATION; ANOREXIA; ASTHMA; BIPOLAR DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRY POWDER; ERECTILE DYSFUNCTION; HUMAN; IMMUNIZATION; LUNG INFECTION; MIGRAINE; NAUSEA AND VOMITING; NEBULIZATION; NEOPLASM; NONHUMAN; PATIENT COMPLIANCE; POSTOPERATIVE PAIN; POWDER INHALER; RELIABILITY; REVIEW; SCHIZOPHRENIA; VACCINATION;

ADMINISTRATION, INHALATION; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; LUNG DISEASES; PHARMACEUTICAL PREPARATIONS; VACCINES;

EID: 78649956856     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.538379     Document Type: Review

References (85)

1. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1:67-86
2. Canton R, Cobos N, Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005;11:690-703
3. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008;21:61-70
4. Sullivan VJ, Mikszta JA, Laurent P, et al. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv 2006;3:87-95
5. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994;7:49-75
6. Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2:198-209
7. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009;49:826-37
8. Worsley MH, Macleod AD, Brodie MJ, et al. Inhaled fentanyl as a method of analgesia. Anaesthesia 1990;45:449-51
9. Dunn C, Curran MP. Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus. Drugs 2006;66:1013-32
10. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 2010;50:169-79
11. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med 2008;102:10-19
12. Le Brun PPH, De Boer AH, Heijerman HG, Frijlink HW. A review of the technical aspects of drug nebulization. Pharm World Sci 2000;22:75-81
13. Le Brun PPH, Brimicombe RW, van Doorne H, Heijerman HGM. The cleaning and disinfection of nebulizers used at home and in a cystic fibrosis centre. Eur Hosp Pharm 2000;6:58-63
14. Voshaar T, App EM, Berdel D, et al. Empfehlungen fur die Auswahl von Inhalationssystemen zur Medikamentenverabreichung. Pneumologie 2001;55:579-86
15. Fradley G, Mahon G. Trends in device selection for inhalation markets - abstracts from the aerosol society drug delivery to the lungs XVI. J Aerosol Med 2006;19:221-41
16. Frijlink HW, De Boer AH. Nebulization and administration devices. In: Bechtold-Peters K, Luessen H, editors, Pulmonary drug delivery. Editio Cantor Verlag, Aulendorf; 2007. p. 124-53
17. Newman SP, Moren F, Trofast E, et al. Terbutaline sulphate turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 1991;74:209-13
18. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003;63:2501-20
19. Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled Amphotericin B. J Aerosol Med Pulm Drug Deliv 2009;22:213-27
20. De Boer AH, Hagedoorn P, Westerman EM, et al. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur J Pharm Sci 2006;28:171-8
21. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124:360-6
22. RelenzaTM Full Prescribing Information (US). GlaxoSmithKline, Research Triangle Park, North Carolina, US, 2010. Available from: products/assets/us- relenza.pdf [Last accessed 19 August 2010]
23. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99
24. Wittgen BPH, Kunst PWA, Perkins WR, et al. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal Cisplatin. J Aerosol Med 2006;19:385-91
25. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50:1161-76
26. Sood DK, Kumar S, Singh S, Sokhey J. Measles vaccination in India and controversies regarding adverse reactions. Vaccine 1995;13:785-6
27. Sabin AB, Arechiga AF, Castro JF, et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine: I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA 1983;249:2651-62
28. Bennett JV, Fernandez Castro J, Valdespino-Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 2002;80:806-12
29. Conlan WJ, Shen H, KuoLee R, et al. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an [alpha] [beta] T cell- and interferon gamma-dependent mechanism. Vaccine 2005;23:2477-85
30. Byron PR. Drug delivery devices: issues in drug development. Proc Am Thorac Soc 2004;1:321-8
31. Newman SP. Dry powder inhalers for optimal drug delivery. Exp Opin Biol Ther 2004;4:23-33
32. Klingler C, Muller BW, Steckel H. Insulin-micro- and nanoparticles for pulmonary delivery. Int J Pharm 2009;377:173-9
33. Thipphawong J. Inhaled cytokines and cytokine antagonists. Challenges and innovations in effective pulmonary systemic and macromolecular drug delivery. Adv Drug Deliv Rev 2006;58:1089-105
34. Klingler C. Insulin mikro- und nanopartikel zur pulmonalen applikation. Dissertation. Kiel, 2009
35. Niven RW. Delivery of biopharmaceutics in inhalation aerosol. 1. Crit Rev Ther Drug Carrier Syst 1995;12:151-232
36. Mather LE, Woodhouse A, Ward ME, et al. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. Br J Clin Pharmacol 1998;46:37-43
37. Thipphawong JB, Babul N, Morishige RJ, et al. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 2003;99:693-700
38. Overhoff KA, Clayborough R, Crowley M. Review of the TAIFUN multidose dry powder inhaler technology. Drug Dev Ind Pharm 2008;34:960-5
39. Yang Z, Le Y, Hu T, et al. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res 2008;25:2012-18
40. van Drooge D, Hinrichs WLJ, Dickhoff BHJ, et al. Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur J Pharm Sci 2005;26:231-40
41. Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction -Efficacy and safety findings. J Sex Med 2010;7:1508-17
42. Becton Dickinson and Company. Medicament respiratory delivery device, cartridge and method of making the same. WO02055133; 2002
43. Huang J, Garmise RJ, Crowder TM, et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 2004;23:794-801
44. Mikszta JA, Sullivan VJ, Dean C, et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 2005;191:278-88
45. Hovione Inter AG. A simple inhaler. WO2007132217; 2007
46. Tibbatts J, Mendes PJ, Villax P. Understanding the power requirements for efficient dispersion in powder inhalers: comparing CFD predictions and experimental measurements. Presented at: Respiratory Drug Delivery 2010. Orlando, Florida, US; 2010
47. Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53:186-92
48. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010;54:2575-82
49. Kubo S, Tomozawa T, Kakuta M, et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 2009;54:1256-64
50. Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 2009;53:4845-51
51. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 2010: published online 9 February 2010, doi:10.1177/ 0091270009356297
52. Ishizuka H, Yoshiba S, Yoshihara K, Okabe H. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its prodrug, CS-8958. J Clin Pharmacol 2010: published online 2 March 2010, doi:10.1177/ 0091270010361914
53. LANI Phase III clinical trials in Asia prove successful. Biota Holdings Limited, Notting Hill, Australia, 2009. Available from: 154/1021542- 25laniphaseiiiclinicaltri.pdf [Last accessed 25 August 2010]
54. Daiichi Sankyo submits a New Drug Application in Japan for CS-8958. Biota Holdings Limited, Notting Hill, Australia, 2010. Available from: http:// www.biota.com.au/uploaded/154/ 1021622-03cs-8958ndafiledinjapan.pdf [Last accessed 25 August 2010]
55. Hoviones TwinCaps dry-powder inhaler filed in Japan for the treatment of influenza. Hovione. Loures, Portugal, 2010. Available from: . hovione.com/h-press/press-rel/ pr2010001-twincaps-japan.htm [Last accessed 19 August 2010]
56. Conix. Cambridge Consultants, Cambridge, UK, 2010. Available from: . cambridgeconsultants.com/cs-conix.html [Last accessed 26 August 2010]
57. M Conix Dry Powder Inhaler. 3M, St. Paul, Minnesota, US, 2010. Available from: portal/3M/en-WW/ DrugDeliverySystems/DDSD/technologysolutions/ inhalation-technology/systems/ dry-powder-inhaler/ [Last accessed 26 August 2010]
58. Needham M, Fradley G, Cocks P. Investigating the efficiency of reverse cyclone technology for DPI drug delivery. Presented at: Respiratory Drug Delivery 2010. Orlando, Florida, US; 2010
59. Smit S, Hagedoorn P, Steckel H, et al. The effect of powder (co-)processing on the dispersibility of tobramycin in the TwincerTM dry powder inhaler. Presented at: 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Valletta, Malta; 2010
60. Hartmann T. Agglomeration feiner Pulver - Ein neues Verfahren zur Softpellet-Produktion. Dissertation. Kiel, 2008
61. De Boer AH, Le Brun PP, van der Woude HG, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm 2002;54:17-24
62. Westerman EM, De Boer AH, Le Brun PPH, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 2007;6:284-92
63. Le Brun PP, De Boer AH, Mannes GP, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002;54:25-32
64. Westerman EM, De Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm 2007;335:41-5
65. Direct-Haler A/S. An inhaler. WO9622802; 1996
66. Keldmann E. Introducing the novel DirectHalerTM DPI technology & philosophy. Presented at: 12th Annual Conference Dry Powder Inhalers. London, UK; 2003
67. Keldmann E. Simplicity wins - from product conceptualisation to drug delivered. Drug Deliv Rep 2006;Summer/Spring:49-52
68. Shidhaye S, Sheetal M, Kadam VJ. Novel drug delivery devices. Pharma Times 2006;38:24-7
69. Aespironics Ltd. Dry powder inhaler. WO2009133555; 2009
70. Aespironics - Company Profile. Maayan Ventures Ltd., Omer, Israel, 2010. Available from: . co.il/21/Aespironics-Ltd. [Last accessed 19 August 2010]
71. Genosar A, Adler D, Kritzman A, et al. Affordable needle-free vaccination technology for low resources settings. Presented at: 6th Annual World Health Care Congress. Washington, D.C., US; 2009
72. Friebel C, Stolte S, Steckel H, Solomon I. Performance of a new single-use disposable dry powder inhaler prototype. Presented at: Respiratory Drug Delivery 2010. Orlando, Florida, US; 2010
73. Noymer P, Myers D, Glazer M, et al. The Staccato system: inhaler design characteristics for rapid treatment of CNS disorders. Presented at: Respiratory Drug Delivery 2010. Orlando, Florida, US; 2010
74. Rabinowitz JD, Wensley M, Lloyd P, et al. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther 2004;309:769-75
75. Dinh KV, Myers DJ, Noymer PD, assella JV. In vitro aerosol deposition in the oropharyngeal region for Staccato loxapine. J Aerosol Med Pulm Drug Deliv 2010;23:1-8
76. Rabinowitz JD, Lloyd PM, Munzar P, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci 2006;95:2438-51
77. Nordstrom K. Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol 2009;4:539-45
78. Alexza Announces Submission of AZ-004 (Staccato Loxapine) NDA. Alexza Pharmaceuticals, Inc. Mountain View, California, US, 2009. Available from: . corporate-ir.net/phoenix.zhtml? c=196151&p=irolnewsArticle&ID= 1365687&highlight= [Last accessed 19 August 2010]
79. Dubin CH. The state of systemic pulmonary delivery: one year after Exuberas approval. Drug Deliv Tech 2007;7:61-7
80. Vectura Group plc Annual Report and Accounts 2006/07. Vectura Group plc, Chippenham, UK, 2007. Available from: Vectura/investors/reports/2007/ vec-ar-2007/vec-ar-2007.pdf [Last accessed 27 August 2010]
81. Devices and formulation technologies. Vectura Group plc, Chippenham, UK, 2010. Available from: . vectura.com/products/proprietary/devices. aspx [Last accessed 27 August 2010]
82. The dry powder for blister based single-dose inhaler inhaler. RPC Formatec GmbH, Mellrichstadt, Germany, 2010. Available from: http:// www.rpc-formatec.de/MonoHaler-en . html [Last accessed 27 August 2010]
83. Disposable inhaler. MannKind Corporation, Valencia, California, US, 2010. Available from: . mannkindcorp.com/disposable-inhaler. aspx [Last accessed 27 August 2010]
84. Technologies-Overview. Manta Devices LLC, Boston, Massachusetts, US, 2010. Available from: . mantadevices.com/Technologies-Overview. html [Last accessed 27 August 2010]
85. Single dose DPI. Manta Devices LLC, Boston, Massachusetts, US, 2010. Available from: . mantadevices.com/Device-Singledose. html [Last accessed 27 August 2010]